Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate

ABSTRACT

In one aspect, the present invention provides a novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate, a key intermediate for the preparation of HMG-CoA reductase inhibitor.

PRIORITY CLAIM

The present application claims the benefit under 35 U.S.C. § 371 of International Application No.: PCT/IN03/00317, filed Sep. 18, 2003, the entire contents of each of this application are hereby incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to a novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate, a key intermediate for the preparation of a HMG CoA reductase inhibitor.

BACKGROUND OF THE INVENTION

HMG CoA reductase inhibitors are pharmaceutically active compounds used for inhibition of cholesterol biosynthesis. A group of compounds called ‘statins’ comprising lovastatin, simvastatin, mevastatin, pravastatin, atorvastatin, rosuvastatin, cerivastatin and fluvastatin show antilipidemic activity and are widely known HMG CoA reductase inhibitors. Ester Derivative of the Formula I

is a valuable chiral synthon for synthesizing atorvastatin.

SUMMARY OF THE INVENTION

In one aspect, the present invention provides a novel process for the preparation of the compound of Formula I. In another aspect, the process employs novel intermediates.

The present invention relates to a novel process for preparing a compound of Formula I

comprising

-   hydrolysis of a compound of Formula II     wherein, the compound of Formula II is obtained from a compound of     Formula III     wherein Alk is a straight or branched C₁-C₆ alkyl; and     wherein the compound of Formula III is obtained from a compound of     Formula IV     wherein Alk is a straight or branched C₁-C₆ alkyl.

The process of the present invention has several advantages over the prior art including: higher yield during conversion of the compound of Formula III to the compound of Formula II as the hydroxy group is protected, reactions after protection with TBDPS can be followed by TLC, low consumption of reagents as the hydroxy group is protected, and reduced levels of undesired side products.

DETAILED DESCRIPTION OF CERTAIN PREFERRED EMBODIMENTS OF THE INVENTION

In one aspect, the present invention provides a novel process for the preparation of Formula I

comprising

-   removal of the TBDPS group from a compound of Formula II     wherein the compound of Formula II is obtained from a compound of     Fromula III     wherein Alk is a straight or branched C₁-C₆ alkyl; and     wherein the compound of Formula III is obtained from a compound of     Formula IV     -   FORMULA IV,         wherein Alk is a straight or branched C₁-C₆ alkyl.

An exemplary process according to the present invention is depicted in Scheme I below:

wherein Alk is a straight or branched C₁-C₆ alkyl.

In one embodiment, the inventive process employs a hydroxy protecting group and utilizes novel intermediates of Formulae II and III. For example, TBDPS (tert-butyl diphenyl silyl) may be employed.

In certain exemplary embodiments, a compound of Formula I may be obtained by removal of the TBDPS group from a compound of Formula II by conventional methods.

In certain other embodiments, a compound of Formula II may be obtained by treating a compound of Formula III with a carbanion, which is generated by the reaction of tert-butyl acetate with lithium diisopropylamide.

In yet other embodiments, a compound of Formula III may be obtained by reacting a compound of Formula IV with tert-butyl diphenyl silyl chloride.

The illustrated embodiments have been set forth only for the purposes of example and should not be taken as limiting the invention. Therefore, it should be understood that, within the scope of the appended claims, the invention may be practiced other than specifically described herein.

Example 1 Ethyl 4-cyano-3-(tert-butyldiphenylsilyloxy)-butanoate

Imidazole (6.5 g, 0.095 mol) was added to a chilled solution (−5 to −10° C.) of ethyl 4-cyano-3-hydroxybutanoate (10 g, 0.063 mol) in dichloromethane (100 ml) under stirring, followed by tert-butyl diphenyl silyl chloride (15.7 g, 0.057 mol). After stirring for 4 hours at room temperature, water (250 ml) was added to the reaction mixture and layers separated. The a queous layer was extracted with dichloromethane (100 ml) and combined with the organic layer. The combined organic layer was evaporated to give title compound.

Yield: 22 g.

Example 2 tert-Butyl 6-cyano-5-(tert-butyldiphenylsilyloxy)-3-oxohexanoate

A solution of n-butyl lithium in hexane (14.4 ml, 0.21 mol) was added to a chilled solution (−5 to −10° C.) of diisopropylamlie (23.2 g, 0.23 mol) in THF (100 ml) and the resulting mixture was stirred at −5 to −10° C. for 30 minutes. After chilling the reaction to about −45° C., tert-butyl acetate (26 g, 0.21 mol) was added and the resulting reaction mixture was stirred at −20-300 C for 1 hour. A solution of ethyl 4-cyano-3-(tert-butyldiphenylsilyloxy)-butanoate (20 g, 0.050 mol) in THF (20 ml) was added to the reaction mixture at about −75° C. and further stirred −70-75° C. for 2 hours. Methanol (15 ml) was added to the reaction mixture followed by water (200 ml) and layers were separated. The organic layer was preserved. The aqueous layer was extracted with ethyl acetate (2×200 ml) and combined with the organic layer. The combined organic layer was evaporated to give the title compound.

Yield: 20 g. 

1. A process for the preparation of a compound of Formula

comprising removing the tert-butyl diphenyl silyl group of a compound of Formula II

wherein the compound of Formula II is obtained by treating a compound of Formula III

wherein Alk is a straight or branched C₁-C₆ alkyl, with a carbanion, generated by the reaction of tert-butyl acetate with lithium diisopropylamide, wherein the compound of Formula III is obtained from reacting a compound of Formula IV

wherein Alk is a straight or branched C₁-C₆ alkyl, with tert-butyl diphenyl silyl chloride.
 2. A compound of Formula II


3. A novel compound of Formula III

wherein Alk is a straight or branched C₁-C₆ alkyl.
 4. The process of claim 1, wherein the compound of Formula I

is used for the preparation of atorvastatin. 